The Risk of Colorectal Cancer in Patients with Ulcerative Colitis
Nowacki T., Brückner M., Eveslage M., Tepasse P., Pott F., Thoennissen N., Hengst K., Ross M., Bettenworth D.
Research article (journal) | Peer reviewedAbstract
Conclusions: Despite the use of modern therapies for UC, CAC rates remain high. In our study, risk factors included disease duration while anti-inflammatory therapies reduced the risk. Effective control of the intestinal inflammation also reduced the disease burden as indicated by decreased risk of requiring colectomy, underscoring the need for sufficient surveillance and anti-inflammatory therapies.
Details about the publication
Journal: Digestive Diseases and Sciences (Dig Dis Sci)
Volume: 60
Issue: 2
Page range: 492-501
Status: Published
Release year: 2014
Language in which the publication is written: English
Link to the full text: http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84921937791&origin=inward
Keywords: Colitis-associated cancer (CAC); Colorectal cancer; Inflammatory bowel disease (IBD); Surveillance; Ulcerative colitis (UC)
Authors from the University of Münster
| Bettenworth, Dominik | Medical Clinic of Internal Medicine B: Gastroenterology and Metabolic Disorders (Med B) |
| Brückner, Markus Georg | Medical Clinic of Internal Medicine B: Gastroenterology and Metabolic Disorders (Med B) |
| Eveslage, Maria | Institute of Biostatistics and Clinical Research (IBKF) |
| Nowacki, Tobias Max | Medical Clinic of Internal Medicine B: Gastroenterology and Metabolic Disorders (Med B) |
| Tepasse, Phil-Robin | Medical Clinic of Internal Medicine B: Gastroenterology and Metabolic Disorders (Med B) |